| Literature DB >> 30410620 |
Gergő Mótyán1, László Mérai1, Márton Attila Kiss1, Zsuzsanna Schelz2, Izabella Sinka2, István Zupkó2, Éva Frank1.
Abstract
Multistep syntheses of novel 17β-pyrazol-5'-ones in the Δ5-androstane series were efficiently carried out from pregnenolone acetate. A steroidal 17-carboxylic acid was first synthesized as a norpregnene precursor by the bromoform reaction and subsequent acetylation. Its CDI-activated acylimidazole derivative was then converted to a β-ketoester containing a two carbon atom-elongated side chain than that of the starting material. A Knorr cyclization of the bifunctional 1,3-dicarbonyl compound with hydrazine and its monosubstituted derivatives in AcOH under microwave heating conditions led to the regioselective formation of 17-exo-heterocycles in good to excellent yields. The suppression of an acid-catalyzed thermal decarboxylation of the β-ketoester and thus a significant improvement in the yield of the desired heterocyclic products could be achieved by the preliminary liberation of the arylhydrazines from their hydrochloride salts in EtOH in the presence of NaOAc. The reaction rates were found to depend on the electronic character of the substituent present in the phenylhydrazine applied. The antiproliferative activities of the structurally related steroidal pyrazol-5'-ones and their deacetylated analogs were screened on three human adherent breast cancer cell lines (MCF7, T47D and MDA-MB-231): the microculture tetrazolium assay revealed that some of the presented derivatives exerted cell growth inhibitory effects on some of these cell lines comparable to those of the reference compound, cisplatin.Entities:
Keywords: Knorr reaction; antiproliferative activity; microwave; pyrazol-5-ones; steroids
Year: 2018 PMID: 30410620 PMCID: PMC6204839 DOI: 10.3762/bjoc.14.236
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Scheme 1Multistep synthesis of steroidal β-ketoesters 4 and 4' from pregnenolone acetate (1) and pregnadienolone acetate (1').
Scheme 2Cyclization of compound 4 with hydrazine hydrate (5a), phenylhydrazine (5b) and methylhydrazine (5c).
Synthesis of steroidal N(1')-aryl-substituted pyrazol-5'-onesa.
| entry | arylhydrazine hydrochloride | R | pyrazol-5-one | irradiation time (min) | yieldb (%) |
| 1 | Me | 10 | 86 | ||
| 2 | iPr | 10 | 90 | ||
| 3 | 10 | 87 | |||
| 4 | OMe | 5 | 92 | ||
| 5 | F | 30 | 85 | ||
| 6 | Cl | 30 | 83 | ||
| 7 | Br | 30 | 85 | ||
aReagents and conditions: arylhydrazine hydrochloride 5d–j·HCl (1.2 equiv), NaOAc (1.2 equiv), EtOH (10 mL), 40 °C, 10 min, then compound 4 (1.0 mmol) in AcOH (20 mL), MW, 120 °C, 5–30 min. bAfter purification by column chromatography.
Figure 11H NMR spectra of compound 7f in CDCl3 (top; # solvent signal) and in DMSO-d6 (bottom; # solvent signal).
Antiproliferative effects of the synthesized compounds on gynecological cell lines and NIH-3T3 fibroblasts.a
| compound | conc. (μM) | inhibition of cell proliferation (%) ± SEM | |||
| MCF7 | MDA-MB-231 | T47D | NIH-3T3 | ||
| 10 | 25.7 ± 1.1 | – | – | n.d. | |
| 30 | 70.0 ± 1.0 | 30.9 ± 2.0 | 58.9 ± 1.0 | ||
| 10 | – | – | 38.2 ± 1.5 | n.d. | |
| 30 | 76.8 ± 0.3 | 72.1 ± 0.4 | 90.9 ± 0.6 | ||
| 10 | – | – | – | n.d. | |
| 30 | 52.2 ± 2.8 | 26.8 ± 1.2 | 83.8 ± 1,3 | ||
| 10 | – | – | – | n.d. | |
| 30 | 35.8 ± 1.1 | – | 51.4 ± 1.7 | ||
| 10 | – | – | – | n.d. | |
| 30 | – | – | 41.7 ± 2.6 | ||
| 10 | – | – | – | n.d. | |
| 30 | 73.8 ± 0.6 | 29.3 ± 3.0 | 72.2 ± 1.7 | ||
| 10 | – | – | – | n.d. | |
| 30 | 47.4 ± 1.5 | – | 60.7 ± 2.2 | ||
| 10 | 65.1 ± 0.9 | – | 74.9 ± 2.4 | – | |
| 30 | 95.1 ± 1.1 | 90.8 ± 0.5 | 84.2 ± 1.6 | 88.3 ± 0.8 | |
| [9.0] | [6.5] | [18.1] | |||
| 10 | – | – | 22.2 ± 1.3 | n.d. | |
| 30 | 87.8 ± 0.7 | 29.2 ± 1.2 | 78.0 ± 0.6 | ||
| 10 | 31.0 ± 1.7 | – | 31.1 ± 2.2 | n.d. | |
| 30 | 86.4 ± 1.4 | 27.0 ± 1.0 | 77.5 ± 1.1 | ||
| 10 | – | – | 57.0 ± 0.9 | n.d. | |
| 30 | – | – | 65.8 ± 1.3 | ||
| 10 | – | – | – | n.d. | |
| 30 | 85.8 ± 1.0 | 40.6 ± 1.7 | 89.6 ± 0.7 | ||
| 10 | – | – | – | n.d. | |
| 30 | 23.1 ± 2.6 | 57.9 ± 2.0 | – | ||
| 10 | – | – | 31.1 ± 1.7 | n.d. | |
| 30 | 27.9 ± 2.7 | – | 60.3 ± 1.9 | ||
| 10 | – | – | – | n.d. | |
| 30 | 66.3 ± 1.5 | – | 95.8 ± 0.2 | ||
| 10 | 21.1 ± 2.8 | 31.3 ± 1.3 | 83.1 ± 1.3 | – | |
| 30 | 95.8 ± 0.3 | 89.6 ± 0.8 | 87.5 ± 0.5 | 84.6 ± 1.3 | |
| [4.3] | [18.2] | ||||
| 10 | – | – | 22.3 ± 1.3 | n.d. | |
| 30 | 40.9 ± 1.6 | 39.6 ± 1.7 | 55.7 ± 2.2 | ||
| 10 | – | – | – | n.d. | |
| 30 | 91.3 ± 0.8 | 96.8 ± 0.2 | 85.2 ± 1.1 | ||
| 10 | 66.8 ± 1.7 | 31.3 ± 1.5 | 32.8 ± 1.3 | – | |
| 30 | 96.3 ± 0.2 | 96.8 ± 0.2 | 87.8 ± 0.5 | 94.0 ± 0.5 | |
| [6.9] | [15.3] | ||||
| 10 | 58.6 ± 1.2 | 42.0 ± 0.8 | 48.3 ± 1.9 | – | |
| 30 | 89.5 ± 1.1 | 96.1 ± 0.2 | 85.5 ± 1.2 | 91.1 ± 1.0 | |
| [8.1] | [17.3] | ||||
| cisplatin | 10 | 66.9 ± 1.8 | – | 51.0 ± 2.0 | 94.2 ± 0.4 |
| 30 | 96.8 ± 0.4 | 71.5 ± 1.2 | 55.0 ± 1.5 | 96.4 ± 0.2 | |
| [5.8] | [19.1] | [9.8] | [3.2] | ||
aCompounds eliciting less than 20% inhibition of proliferation were considered ineffective and the exact results are not given, for simplicity. n.d.: not determined.